Skin & Appearance
    Body Changes

    Ozempic Butt: Body Shape Changes on Weight Loss Medication

    Why GLP-1 medications change your body shape, what "Ozempic butt" really is, and how to maintain curves while losing weight.

    Published: March 17, 202613 min read

    Medical Disclaimer

    This article is for educational purposes only and does not constitute medical advice. Body shape changes during weight loss are normal and vary by individual. Consult your healthcare provider with specific concerns.

    First there was "Ozempic face." Now social media, celebrity gossip, and patient forums have coined a new term: "Ozempic butt." The phenomenon describes the flattened, deflated, or sagging appearance of the buttocks that some patients notice during significant weight loss on GLP-1 receptor agonists. But how common is it really, and what can you do about it?

    What Actually Happens to Your Body Shape on GLP-1 Medications

    GLP-1 medications do not selectively target any specific fat depot. They work by reducing appetite, slowing gastric emptying, and modifying brain reward signals related to food -- leading to reduced caloric intake and overall fat loss. Your body decides where to lose fat based on genetics, hormones, age, and sex.

    However, the pattern of fat loss is not random. Research shows that GLP-1 medications like semaglutide produce significant reductions in visceral fat (the dangerous fat surrounding organs) and subcutaneous fat throughout the body. The buttocks are primarily composed of three gluteal muscles (gluteus maximus, medius, and minimus) covered by a substantial layer of subcutaneous fat. When that fat layer shrinks, the shape of the buttocks changes.

    The degree of change depends on several factors. Women typically store more fat in the gluteal-femoral region (hips, buttocks, thighs) than men, so they may notice more dramatic changes in these areas. Genetics determine fat distribution patterns -- some people carry proportionally more gluteal fat than others. Age affects how skin responds to volume loss -- younger patients' skin adapts more readily. And the total amount of weight lost matters: losing 20 pounds may cause minimal change, while losing 60+ pounds often produces noticeable reshaping.

    It's Not Just the Butt: Full Body Reshaping

    "Ozempic butt" gets attention because it is visible and culturally significant, but GLP-1 weight loss reshapes the entire body. Patients commonly report changes in breast volume (often one of the first areas where fat loss is noticeable), waist-to-hip ratio shifts, arm and thigh circumference reduction, face thinning, and changes in how clothing fits across the body. Understanding that body reshaping is a comprehensive process helps set realistic expectations. You cannot selectively preserve fat in desired areas while losing it from others through medication alone.

    Who Notices the Most Change?

    Patients most likely to experience significant gluteal changes include those who carry a high proportion of body fat in the hip and buttock region (pear-shaped body type), women going through perimenopause or menopause (when fat redistribution patterns shift), patients losing more than 50 pounds total, patients who do not engage in resistance training during treatment, and those with lower starting muscle mass in the gluteal area.

    Conversely, patients who carry weight primarily in the abdomen (apple-shaped), men (who typically have less gluteal fat), those who maintain a strength training program, and patients with naturally muscular builds tend to notice less dramatic gluteal changes.

    The Exercise Solution: Building What Fat Leaves Behind

    The most effective strategy for preventing "Ozempic butt" is building gluteal muscle to replace lost fat volume. Muscle is denser than fat and provides a firm, rounded shape. Even modest gluteal hypertrophy can dramatically improve the appearance of the buttocks.

    The Best Exercises for Gluteal Development

    Targeted Gluteal Training Program

    Primary Movements (3 sets of 8-12 reps)

    • Hip thrusts: The single most effective gluteal exercise. Use a barbell, dumbbell, or resistance band.
    • Bulgarian split squats: Excellent for gluteal activation with unilateral leg work.
    • Romanian deadlifts: Targets the glute-hamstring connection for a lifted appearance.

    Secondary Movements (3 sets of 12-15 reps)

    • Cable kickbacks: Isolates the gluteus maximus through hip extension.
    • Lateral band walks: Targets the gluteus medius for side-body roundness.
    • Step-ups: Functional movement with excellent gluteal activation.

    Frequency

    Train glutes 2-3 times per week with at least 48 hours between sessions for recovery. Progressive overload (gradually increasing weight) is essential.

    The key to gluteal muscle development while on GLP-1 medication is adequate protein intake. Building muscle requires amino acids, and reduced appetite can make it difficult to consume enough. Aim for at least 1.4-1.6 grams of protein per kilogram of body weight daily when actively trying to build muscle. Prioritize protein timing around workouts -- consuming 20-40 grams of protein within 2 hours of training optimizes muscle protein synthesis.

    Can You Actually Build Muscle While Losing Weight?

    Yes, especially for people new to resistance training. This phenomenon, called "body recomposition," is most achievable in individuals who are new to weightlifting, carry significant excess body fat, maintain adequate protein intake, and follow a well-designed progressive training program. Even patients who cannot build new muscle can preserve existing muscle mass through resistance training -- preventing the accelerated muscle loss that occurs when weight loss happens without exercise.

    Non-Exercise Strategies

    Strategic clothing: High-waisted, structured pants and compression leggings can provide lift and shape during the transition period. Many patients find that updating their wardrobe is a positive experience that reinforces their weight loss achievement.

    Nutrition optimization: Beyond protein, ensure adequate caloric intake to support muscle development. Being too aggressive with caloric restriction on top of GLP-1 appetite suppression can accelerate muscle loss throughout the body, including the glutes.

    Collagen supplementation: While primarily discussed for skin health, collagen peptides support the connective tissue that gives the buttocks their shape and structure. Consider 10-15 grams daily of hydrolyzed collagen peptides.

    Cosmetic Procedures for Gluteal Enhancement

    For patients who want more dramatic results after weight loss has stabilized, several cosmetic options exist. It is important to wait until weight has been stable for at least 6 months before pursuing these procedures.

    • Brazilian butt lift (BBL): Transfers fat from another body area to the buttocks. This option may be limited in patients who have lost significant fat stores. Requires sufficient donor fat. Recovery: 4-6 weeks.
    • Gluteal implants: Silicone implants placed within or on top of the gluteal muscles. Provides consistent, predictable volume regardless of body fat. Recovery: 4-6 weeks.
    • Sculptra injections: Poly-L-lactic acid injected into the buttocks stimulates collagen production and gradually increases volume over several months. Non-surgical option requiring multiple sessions.
    • Buttock lift: Removes excess skin and lifts sagging tissue. Often combined with a lower body lift for comprehensive contouring.

    A Word About Body Image

    The conversation around "Ozempic butt" reflects broader cultural anxieties about body shape and the pressure to conform to specific beauty standards. It is worth remembering that the primary purpose of GLP-1 medications is metabolic health -- reducing cardiovascular risk, improving insulin sensitivity, and treating obesity as a chronic disease.

    Body shape changes are a natural consequence of significant weight loss by any method. Many patients find that while their body shape differs from what they expected or hoped, their overall health, energy, mobility, and quality of life improve dramatically. Working with a therapist who specializes in body image can be valuable during this transition.

    The Bottom Line

    "Ozempic butt" is a real phenomenon caused by the natural loss of gluteal fat during significant weight loss. It is not unique to GLP-1 medications -- any substantial weight loss can produce similar changes. The most effective prevention is a consistent gluteal resistance training program paired with adequate protein intake. For those who desire additional enhancement after weight stabilization, both non-surgical and surgical options are available.

    Starting a comprehensive fitness program alongside your GLP-1 treatment provides the best results. Learn about Trimi's integrated weight loss programs that include lifestyle and exercise guidance alongside medical treatment.

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Body shape changes during weight loss are individual and vary significantly. Consult your healthcare provider and a certified fitness professional for personalized exercise recommendations.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for compounded semaglutide?

    Peer-reviewed evidence: Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021). Trimi offers compounded semaglutide starting at $99/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. — STEP 1, NEJM 2021
    Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. — STEP 4, JAMA 2021
    Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. — SELECT, NEJM 2023

    Key Takeaways

    • Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021)
    • Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. (Source: STEP 4, JAMA 2021)
    • Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. (Source: SELECT, NEJM 2023)
    • Semaglutide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Wegovy and Ozempic). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: October 9, 2025

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    I'm on my 4th week. No side effects. 5 lb loss which seems slow to me. Food noise is much better. We shall see!

    Outcome: 5 lbs lost in 4 weeks; no side effects; food noise reduced

    Lynn SchweitzerFacebook
    21 lbs down in 6 weeks! So happy I started with you guys!

    Outcome: 21 lbs lost in 6 weeks

    Robyn Lynn CurtisFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    3. Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-022-02026-4
    4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2307563
    5. Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa1607141
    6. Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2403347

    Was this article helpful?

    Keep Reading

    Learn what Ozempic face is, who is most at risk, and evidence-based strategies to prevent facial volume loss during GLP-1 weight loss. Expert dermatology insights and practical prevention tips.

    Comprehensive guide to preventing and treating loose skin during GLP-1 weight loss. Evidence-based strategies for skin elasticity, collagen support, and when to consider surgical options.

    Understand why GLP-1 weight loss medications can cause sagging or flattening of the buttocks, what drives these body shape changes, and strategies for prevention and treatment.

    Detailed comparison of retatrutide vs orforglipron: injectable triple agonist vs the first oral GLP-1 pill. Weight loss data, convenience, side effects, and which might be right for you.

    Start your GLP-1 journey — from $99/mo

    Get Started